82
Participants
Start Date
April 24, 2023
Primary Completion Date
April 17, 2025
Study Completion Date
April 17, 2026
BPI-460372
Subjects will receive BPI-460372 until disease progression
RECRUITING
Peking Union Medical College Hospital, Beijing
NOT_YET_RECRUITING
China-Japan Union Hospital of Jilin University, Changchun
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Central Hospital Affiliated to Shandong First Medical University, Jinan
NOT_YET_RECRUITING
Shandong Cancer Hospital, Jinan
NOT_YET_RECRUITING
Taizhou Hospital of Zhejiang Province, Taizhou
RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Tongji Hospital Tongji Medical College of HUST, Wuhan
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
RECRUITING
Affiliated Hospital of Hebei University, Baoding
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
INDUSTRY